Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB01 Cream in Chronic Allergic Contact Dermatitis
NCT03680131Phase 2Completed
- Sponsor
- Edesa Biotech, Inc.
- Start
- Oct 2019
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of daniluromer in allergic contact dermatitis (ACD), sponsored by Edesa Biotech, Inc.. Started Oct 2019; status: completed.
02
Drugs
daniluromer
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT03680131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680131.